MicroPort Scientific : Altura™ Endograft System Granted CFDA Green-Path

Shanghai, China - On December 6, Altura™ Endograft System ('Altura™'), distributed by MicroPort Endovascular (Shanghai) Co., Ltd. ('MicroPortEndovascular') and developed by UK-based Lombard Medical, Inc. ('Lombard Medical'), was granted to enter the special Green-Path by China Food and Drug Administration ('CFDA'), which is rapid-track of review and approval procedure for innovative medical devices.

In recent years, with the aging global population and improvement of diagnosis technology, the morbidity and definitive diagnosis rate of abdominal aortic aneurysm ('AAA') is increasing year by year. AAA is not self-healing. If the AAA patients can't be treated in time, they may die from aneurysm rupture. Endovascular aortic repair ('EVAR') has been the primary solution of high-risk AAA. Currently, branched stent-graft is the most commonly used device in EVAR treatment. Altura™ is the world's first and only device boldly and effectively evolving the conventional bifurcated main body into unique Bilateral D-Stent Design, with ultra-low profile of 14F. The unique Bilateral D-Stent Design of Altura™ enables the offset aortic endografts to be independently positioned, maximizing seal in infrarenal neck. Besides, the proximal portion of the aortic endografts with the design of uncovered suprarenal bare stent and active anchor fixation minimizes the occurrence rate of complications of endoleak and stent migration, to provide a simple, reliable solution for physicians in the treatment of AAA.

Previously, the Altura™ system received CE Mark in 2015. In April 2017, MicroPort Scientific Corporation ('MPSC') signed an agreement with Lombard Medical which provides MPSC with the exclusive marketing rights for Lombard Medical's products Aorfix™ and Altura™ AAA stent graft product lines in China and Brazil, as well as the right to a technology license to manufacture the products for the China market.

From 2015 to 2017, four products in-house developed by MicroPortEndovascular, including Castor™ Branched Aortic Stent Graft System, Reewarm™ PTX Drug Coated Balloon Dilation Catheter, Minos™ Ultra Low-Profile AAA Stent-Graft System, and Talos™ Thoracic Stent Graft System, had entered into the CFDA Green-Path. Altura™ is first imported product of MicroPortEndovascular that gained the CFDA Green-Path, which shows government authority's recognition in its innovation and will accelerate its approval procedure. It is expected that the launch of Altura™ will help promote the application of the new product and technology in China's endovascular repair industry, and thereby benefit more local patients.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]